Target intelligence / Profile preview

Protein mago nashi homolog B (MAGOHB)

Target
MAGOHB
Molecular classification
Other (EJC core protein/exon junction complex subunit), RNA-binding protein
01

Overview

Protein mago nashi homolog B (MAGOHB) is a core member of the exon junction complex (EJC), a multi-protein assembly that binds to mRNA near exon-exon junctions following splicing[1][2][4]. MAGOHB, together with its paralog MAGOH, partners with other EJC core proteins (eIF4A3, Y14) to regulate post-transcriptional processes, including mRNA export, localization, translation, and notably nonsense-mediated decay (NMD) to eliminate faulty mRNAs[1][2][4]. High MAGOHB expression is seen in malignant tumors such as glioblastoma and melanoma, where it is implicated in enhanced cell proliferation and survival. Knockdown studies indicate that depletion of MAGOHB (alone or combined with MAGOH) disrupts splicing precision, impairs NMD, and promotes apoptosis, suggesting that the EJC’s RNA surveillance role is critical for rapidly dividing cells[1][4]. MAGOHB is not typically classified as a classic drug target (receptor, enzyme, ion channel), but its fundamental roles in RNA biology and cancer make it a protein of interest for basic research and potential future interventions[1][2][4].

Other names
MAGOH2MGN2mago homolog Bmago-nashi homolog Bprotein mago nashi homolog 2magohMAGOFLJ10292
02

Mechanism of action

null

03

Biological functions

mRNA splicingNonsense-mediated mRNA decay (NMD)RNA metabolism (processing, export, surveillance)Cell proliferationCell cycle regulationApoptosis (indirectly, via NMD pathways)
04

Disease associations

Cancer (notably in melanoma and glioma/glioblastoma, where overexpression is linked to tumor growth and poor prognosis)Potentially neurodevelopmental disorders (as an EJC component important for nervous system development)
05

Safety considerations

Potential challenges in targeting essential RNA processing proteins due to risk of affecting normal cell splicing, viability, and general gene expression integrity
06

Biomarkers

High expression associated with poor prognosis in glioma/glioblastoma and melanoma; may serve as a prognostic marker in these cancers

Beyond the preview

Go deeper on Protein mago nashi homolog B (MAGOHB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein mago nashi homolog B (MAGOHB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call